Comparison of the imaging performances for recently developed monolithic scintillators: CRY018 and CRY019 for dual isotope gamma ray imaging applications

The growing interest for new scintillation crystals with outstanding imaging performances (i.e. resolution and efficiency) has suggested the study of recently discovered scintillators named CRY018 and CRY019. The crystals under investigation are monolithic and have shown enhanced characteristics both for gamma ray spectrometry and for Nuclear Medicine imaging applications such as the dual isotope imaging. Moreover, the non-hygroscopic nature and the absence of afterglow make these scintillators even more attractive for the potential improvement in a wide range of applications. These scintillation crystals show a high energy resolution in the energy range involved in Nuclear Medicine, allowing the discrimination between very close energy values. Moreover, in order to prove their suitability of being powerful imaging systems, the imaging performances like the position linearity and the intrinsic spatial resolution have been evaluated obtaining satisfactory results thanks to the implementation of an optimized algorithm for the images reconstruction. © 2017 IOP Publishing Ltd and Sissa Medialab srl

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases

We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of these patients. Forty patients received modified FOLFIRI: irinotecan 180 mg m−2, day 1; folinic acid, 200 mg m−2; and 5-fluorouracil: as a 400 mg m−2 bolus, days 1 and 2, and a 48-h continuous infusion 1200 mg m−2, from day 1. Treatment was repeated every 2 weeks, with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen (47.5%) of 40 patients achieved an objective response; 13 (33%) underwent resection. After a median follow-up of 56 months, median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial

Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC). Preclinical evidence suggests that the sequential administration of IRI and FU produces synergistic activity, although their clinical use has not been fully optimised. We investigated the interaction between short-term exposure to SN-38, the active metabolite of IRI, and prolonged exposure to FU in human CRC HT-29 cells and observed that the synergism of action between the two agents can be increased by extending the time of cell exposure to FU and reducing the interval between administration of the two agents. Based on these findings, we performed a phase I trial in 25 advanced CRC patients using a modified IRI/FU regimen as first-line therapy and evaluated three dose levels of IRI (150–300 mg/m2) and two of continuous infusion of FU (800–1000 mg/m2) in a 3-weekly schedule. The most severe grade III–IV toxicities were neutropoenia in four cycles and diarrhoea in three. One patient achieved complete response (4%), 12 a partial response (48%), the overall response rate was 52% (±20, 95% CI); seven of 25 patients had stable disease (28%), the overall disease control was 80% (±16, 95% CI). This modified IRI/FU schedule is feasible and exhibits potentially interesting clinical activity

New insights in the relation between climate and slope failures at high-elevation sites

Climate change is now unequivocal; however, the type and extent of terrestrial impacts are still widely debated. Among these, the effects on slope stability are receiving a growing attention in recent years, both as terrestrial indicators of climate change and implications for hazard assessment. High-elevation areas are particularly suitable for these studies, because of the presence of the cryosphere, which is particularly sensitive to climate. In this paper, we analyze 358 slope failures which occurred in the Italian Alps in the period 2000–2016, at an elevation above 1500 m a.s.l. We use a statistical-based method to detect climate anomalies associated with the occurrence of slope failures, with the aim to catch an eventual climate signal in the preparation and/or triggering of the considered case studies. We first analyze the probability values assumed by 25 climate variables on the occasion of a slope-failure occurrence. We then perform a dimensionality reduction procedure and come out with a set of four most significant and representative climate variables, in particular heavy precipitation and short-term high temperature. Our study highlights that slope failures occur in association with one or more climate anomalies in almost 92% of our case studies. One or more temperature anomalies are detected in association with most case studies, in combination or not with precipitation (47% and 38%, respectively). Summer events prevail, and an increasing role of positive temperature anomalies from spring to winter, and with elevation and failure size, emerges. While not providing a final evidence of the role of climate warming on slope instability increase at high elevation in recent years, the results of our study strengthen this hypothesis, calling for more extensive and in-depth studies on the subject

Imaging characterization of a new gamma ray detector based on CRY019 scintillation crystal for PET and SPECT applications

In the last 40 years, in the field of Molecular Medicine imaging there has been a huge growth in the employment and in the improvement of detectors for PET and SPECT applications in order to reach accurate diagnosis of the diseases. The most important feature required to these detectors is an high quality of images that is usually obtained benefitting from the development of a wide number of new scintillation crystals with high imaging performances. In this contest, features like high detection e ciency, short decay time, great spectral match with photodetectors, absence of afterglow and low costs are surely attractive. However, there are other factors playing an important role in the realization of high quality images such as energy and spatial resolutions, position linearity and contrast resolution. With the aim to realize an high performace gamma ray detector for PET and SPECT applications, this work is focused on the evaluation of the imaging characteristics of a recently developed scintillation crystal, CRY019